What happened with SLN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Silence Therapeutics is a clinical-stage biotechnology company developing medicines for rare and common diseases. Its mRNAi GOLD platform designs small interfering RNA, or siRNA, molecules that enter liver cells and reduce the activity of selected genes linked to disease. It has no approved medicines and has never earned revenue from product sales.
Pharmaceutical partners pay for access to its technology and development work. Under its AstraZeneca collaboration, AstraZeneca chooses gene targets, Silence designs drug candidates and supplies material for early studies, and AstraZeneca leads clinical development and commercialization. Silence receives upfront and target-option payments, with further payments tied to development and commercial milestones and potential royalties on future sales. AstraZeneca and the former Hansoh collaboration have supplied a significant share of collaboration revenue.
Those payments depend on partners continuing programs and candidates advancing. Hansoh ended further development in December 2024, leaving Silence with global rights to the evaluated targets. In March 2026, AstraZeneca said it would stop developing SLN312 after Phase 1; Silence will regain global rights after that trial and is evaluating next steps. Continued development requires additional funding, while any future drug sales require successful trials and regulatory approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Amgen's olpasiran competes directly with Silence Therapeutics' zerlasiran: both are siRNA treatments designed to lower lipoprotein(a) in patients at cardiovascular risk.
Eli Lilly's lepodisiran and muvalaplin compete with Silence Therapeutics' zerlasiran to lower lipoprotein(a) in patients at cardiovascular risk.
Novartis's pelacarsen targets an overlapping patient population with Silence Therapeutics' zerlasiran; both aim to lower lipoprotein(a) and reduce cardiovascular risk.
AstraZeneca pays Silence Therapeutics to use its siRNA technology and to design and develop drug candidates, making its research activity and milestone decisions important to Silence's revenue. AstraZeneca said in March 2026 that it would not develop SLN312 beyond Phase 1; Silence will regain global rights after that trial.
Arrowhead and Silence Therapeutics compete for cardiometabolic treatments and pharmaceutical partners with medicines that silence genes in liver cells, an approach called RNA interference. Arrowhead's REDEMPLO won US approval in 2025 to lower triglycerides alongside diet in adults with familial chylomicronemia syndrome—a concrete commercial step to watch in this field.
Alnylam and Silence Therapeutics compete for pharmaceutical partners and treatment opportunities with siRNA medicines that target liver cells. Watch Alnylam's zilebesiran collaboration with Roche, which pays development milestones and royalties outside the US and shares US profits and losses—a concrete example of how partners fund this approach.
Ionis Pharmaceuticals and Silence Therapeutics compete with RNA-targeted treatments that control hepcidin and iron metabolism. Ionis's progress in those treatments, rather than its broader marketed-drug portfolio, is the news most relevant to this rivalry.
Disc Medicine's DISC-3405 and Silence Therapeutics' SLN124 pursue the same route: inhibiting TMPRSS6 to raise hepcidin and alter iron availability.
ADARx Pharmaceuticals and Silence Therapeutics both depend on clinical validation and pharmaceutical licensing demand for chemically optimized siRNA medicines, with liver-directed programs in trials. ADARx's AbbVie collaboration pays for access to new siRNA therapies through upfront consideration, potential option and milestone payments, and royalties, making its partnership progress worth watching alongside its liver programs.
Wave Life Sciences and Silence Therapeutics both develop chemically engineered RNA medicines, use GalNAc to deliver them to liver cells, and license their platforms to pharmaceutical partners. Watch GSK's selection of Wave programs for further development: GSK prepays their research costs, and those selections have brought Wave additional payments.
AstraZeneca PLC earningsAZN
AstraZeneca’s report will show whether the research it funds with Silence Therapeutics is still moving forward, a direct source of Silence’s collaboration revenue.
Look for AstraZeneca to report continued collaboration work or new program decisions, then compare that with Silence Therapeutics’ own collaboration revenue. Continued activity would show AstraZeneca is still funding research that can generate revenue for Silence; limited activity with no new milestones would mean less revenue support from the partnership, while Silence must plan and fund SLN312 development after Phase 1.
Silence Therapeutics Plc earningsThis company
Silence Therapeutics relies on partner-funded research and milestone payments, and this report will show how collaboration activity and research spending shape its funding runway.
Read collaboration revenue alongside research spending, and check the reported cash and U.S. Treasury balance and how long management says funds will last. A recovery in collaboration revenue with controlled spending and a sustained runway would show partner activity can support the pipeline; persistently low collaboration revenue while spending consumes cash would show greater need for new partner payments or financing to keep developing candidates.
